| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Neurology Service, St. Elizabeth's Medical Center, Boston, MA.
Received May 15, 1996. Accepted in final form July 10, 1996.
Address correspondence and reprint requests to Dr. Kenneth C. Gorson, Division of Neurology, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135.
Article abstract-We report the clinical and EMG details of 67 consecutive patients with strictly defined chronic inflammatory demyelinating polyneuropathy (CIDP) during a 4-year period and compare responses to treatment in patients with idiopathic CIDP (CIDP-I) and CIDP with monoclonal gammopathy of uncertain significance (CIDP-MGUS). Patients were examined an average of 28 months after first symptoms. There were several variant presentations that still conformed to the clinical and electrophysiologic definitions of CIDP, including a pure motor syndrome (10%), sensory ataxic variant (12%), mononeuritis multiplex pattern (9%), paraparetic pattern (4%), and relapsing acute Guillain-Barre syndrome (16%). Pain was more frequent than in previous studies (42%). Conduction block was the commonest EMG abnormality (detected in at least one nerve in 73% of patients), but only 31% had a pure demyelinating neuropathy and the majority had some degree of axonal change. Patients with CIDP-MGUS had less severe weakness, greater imbalance, leg ataxia, vibration loss in the hands, and absent median and ulnar sensory potentials, but were as likely as CIDP-I patients to respond to plasma exchange. Seventeen of 44 patients (39%) with idiopathic CIDP improved for at least 2 months with an initial therapy. Although the response rates among plasma exchange, IVIG, and steroids were similar, functional improvement (Rankin score) was greatest with plasma exchange. Of 26 patients who failed to respond to an initial therapy, 9 (35%) benefited from an alternative treatment, and of the 11 who required a third modality 3 (27%) improved. Overall, 66% responded to one of the three main therapies for CIDP.
NEUROLOGY 1997;48: 321-328
This article has been cited by other articles:
|
|
 |
|
  X. J. Caro, E. F. Winter, and A. J. Dumas A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg Rheumatology, February 1, 2008; 47(2): 208 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oyama, R. Sufit, Y. Loh, L. Statkute, K. Yaung, K. Quigley, E. Gonda, D. Spahovic, D. Bronesky, and R. K. Burt NONMYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CIDP Neurology, October 30, 2007; 69(18): 1802 - 1803. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung Chronic Inflammatory Demyelinating Polyneuropathy N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lopate, A. Pestronk, and M. Al-Lozi Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone Arch Neurol, February 1, 2005; 62(2): 249 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Gorson, A. A. Amato, and A. H. Ropper Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy Neurology, August 24, 2004; 63(4): 715 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-P Lefaucheur, N A Gregson, I Gray, F von Raison, M Bertocchi, and A Creange A variant of multifocal motor neuropathy with acute, generalised presentation and persistent conduction blocks J. Neurol. Neurosurg. Psychiatry, November 1, 2003; 74(11): 1555 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Sander and N. Latov Research criteria for defining patients with CIDP Neurology, April 22, 2003; 60(90083): S8 - 15. [Abstract] [Full Text]
|
|
|
|
|
|
A. H. Ropper Current treatments for CIDP Neurology, April 22, 2003; 60(90083): S16 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
H. W. Sander and E. T. Hedley-Whyte Case 6-2003 - A Nine-Year-Old Girl with Progressive Weakness and Areflexia N. Engl. J. Med., February 20, 2003; 348(8): 735 - 743. [Full Text] [PDF]
|
|
|
|
|
|
A. Mygland and P. Monstad Chronic Acquired Demyelinating Symmetric Polyneuropathy Classified by Pattern of Weakness Arch Neurol, February 1, 2003; 60(2): 260 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Brannagan III Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S33 - 40. [Abstract] [Full Text]
|
|
|
|
|
|
T.H. Brannagan III, A. Pradhan, T. Heiman-Patterson, A.C. Winkelman, M.J. Styler, D.L. Topolsky, P.A. Crilley, R.J. Schwartzman, I. Brodsky, and D.E. Gladstone High-dose cyclophosphamide without stem-cell rescue for refractory CIDP Neurology, June 25, 2002; 58(12): 1856 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Sharma, J. Cross, D. R. Ayyar, A. Martinez-Arizala, and W. G. Bradley Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy Arch Neurol, May 1, 2002; 59(5): 751 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Sharma, J. Cross, O. Farronay, D. R. Ayyar, R. T. Shebert, and W. G. Bradley Demyelinating Neuropathy in Diabetes Mellitus Arch Neurol, May 1, 2002; 59(5): 758 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Gorson, A. H. Ropper, D. H. Weinberg, and R. Weinstein Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy Arch Neurol, May 1, 2002; 59(5): 766 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.R. Mendell, R.J. Barohn, M.L. Freimer, J.T. Kissel, W. King, H.N. Nagaraja, R. Rice, W.W. Campbell, P.D. Donofrio, C.E. Jackson, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy Neurology, February 27, 2001; 56(4): 445 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes Arch Neurol, August 1, 1999; 56(8): 1025 - 1027. [Full Text] [PDF]
|
|
|
|
|
|
D. Karussis and O. Abramsky Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No Arch Neurol, August 1, 1999; 56(8): 1028 - 1032. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Antoine, J.-F. Mosnier, L. Absi, P. Convers, J. Honnorat, and D. Michel Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies J. Neurol. Neurosurg. Psychiatry, July 1, 1999; 67(1): 7 - 14. [Abstract] [Full Text]
|
|
|
|
|
|
R. D. M. Hadden, B. Sharrack, S. Bensa, S. E. Soudain, and R. A. C. Hughes Randomized trial of interferon {beta}-1a in chronic inflammatory demyelinating polyradiculoneuropathy Neurology, July 1, 1999; 53(1): 57 - 57. [Abstract] [Full Text]
|
|
|
|
|
|
D. Leppert, P. Hughes, S. Huber, B. Erne, C. Grygar, G. Said, K. M. Miller, A. J. Steck, A. Probst, and P. Fuhr Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy Neurology, July 1, 1999; 53(1): 62 - 62. [Abstract] [Full Text]
|
|
|
|
|
|
H. C Wilson, M. P T Lunn, S. Schey, and R A C Hughes Successful treatment of IgM paraproteinaemic neuropathy with fludarabine J. Neurol. Neurosurg. Psychiatry, May 1, 1999; 66(5): 575 - 580. [Abstract] [Full Text]
|
|
|
|
|
|
M P T Lunn, H Manji, P P Choudhary, R A C Hughes, and P K Thomas Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England J. Neurol. Neurosurg. Psychiatry, May 1, 1999; 66(5): 677 - 680. [Abstract] [Full Text]
|
|
|
|
|
|
C. Bouchard, C. Lacroix, V. Plante, D. Adams, F. Chedru, J.-M. Guglielmi, and G. Said Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy Neurology, February 1, 1999; 52(3): 498 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Ropper and K. C. Gorson Neuropathies Associated with Paraproteinemia N. Engl. J. Med., May 28, 1998; 338(22): 1601 - 1607. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Gominak and D. P. Cros Case 13-1998- A 23-Year-Old Man with Progressive Weakness and Paresthesias N. Engl. J. Med., April 23, 1998; 338(17): 1212 - 1219. [Full Text] [PDF]
|
|
|
|
|
|
K. C Gorson and A. H Ropper Axonal neuropathy associated with monoclonal gammopathy of undetermined significance J. Neurol. Neurosurg. Psychiatry, August 1, 1997; 63(2): 163 - 168. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
